Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
MS 및 NMOSD 환자에서 리툭시맙과 COVID-19 감염 위험 및 그 심각성
Research
[키워드] case sery
collected
conducted
Corticosteroid
Corticosteroids
Course
COVID-19
COVID-19 infection
COVID-19 pandemic
determine
disability
discharged
disease
Disease modifying therapy
enrolled
evaluated
expired
exposure to
fatality
FIVE
Hospitalization
hospitalizations
ICU admission
incidence
incidence rate
indicated
infected individual
Infection
information
Injections
Mild
mild to moderate
moderate
MS
Multiple
multiple sclerosis
Neuromyelitis Optica
NMO
Occurrence
outcome
pandemic
Patient
patients died
patients treated
positive
Positive test
questionnaire
receiving
reported
required
Result
risk of COVID-19
rituximab
Safe
sclerosis
Self-isolation
severity
subject
Symptom
test results
therapy
two patients
use of corticosteroid
walking disability
[DOI] 10.1186/s12883-021-02218-4 PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s12883-021-02218-4 PMC 바로가기 [Article Type] Research